Targeted Myeloid Engager and Phagocytosis Platform

Harnessing myeloid cells for targeted depletion

A bispecific antibody technology that engages a novel phagocytic receptor selectively expressed on myeloid cells.

Potent depletion, engineered for control

Dren Bio's platform induces potent depletion of pathogenic cells, protein aggregates and other disease-causing agents. Bispecific antibodies generated from the platform are specifically engineered to enable controlled myeloid cell activation only in the presence of the target antigen, which may result in greater therapeutic indexes and superior safety profiles compared to other modalities such as T-cell engagers and antibody drug conjugates.

Illustration of a bispecific antibody engaging a myeloid cell

A multi-pronged mechanism of action

  1. (i)

    Couple

    Bispecific antibodies directly couple myeloid cells with pathogenic cells or other disease-causing agents.

  2. (ii)

    Activate

    Engagement stimulates the release of key cytokines known to reprogram tumor-associated macrophages and reset an immunosuppressive microenvironment.

  3. (iii)

    Engulf

    Myeloid cells phagocytose and kill target cells, clearing the agents that drive disease.

  4. (iv)

    Present

    Presentation of tumor neoantigens can activate effector and memory T cell responses for longer-lasting immunity.

Activation that waits for the target

In multiple non-human primate studies, the first platform candidate showed a favorable preclinical safety profile with no cytokine release syndrome or neurotoxicity observed.

Myeloid-selective receptor
A conserved phagocytic receptor highly expressed on monocytes, macrophages and dendritic cells.
Target-gated activation
Myeloid cells are activated only in the presence of the target antigen, not systemically.
Localized cytokine release
Designed for an increased therapeutic index and a more favorable safety profile.

One platform, three therapeutic areas

Oncology

Platform bispecifics engage myeloid cells to deplete tumor cells and cross-present antigens. DR-0202 initiated a first-in-human study across multiple solid tumor indications in June 2025.

Immunology

Deep, selective depletion of pathogenic B cells and autoreactive cells, with the potential to achieve an immune reset in multiple autoimmune diseases.

Neurology

Removal of harmful protein aggregates, with platform data against targets associated with forms of amyloidosis and Alzheimer's disease.

View pipeline